secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001171843-25-001422
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M
-----------------------------------------------------------------------

- Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.
- Full-year 2024 revenue $94.1M vs $112.3M; net loss $(12.4)M vs $(3.4)M.
- Adjusted EBITDA fell to $7.2M from $14.6M; operating cash flow dropped to $1.4M from $14.0M.
- CEO cites challenging market; highlights SoHo telemetry and MeshMEA organoid systems as growth drivers.
- Q4 net income was $18K vs loss of $(1.8)M in Q4 2023 (slight improvement in quarter).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/0001171843-25-001422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325001422/f8k_031225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer